, Volume 10, Issue 1, pp 2–18

Interferon Beta and Glatiramer Acetate Therapy


DOI: 10.1007/s13311-012-0163-4

Cite this article as:
McGraw, C.A. & Lublin, F.D. Neurotherapeutics (2013) 10: 2. doi:10.1007/s13311-012-0163-4


Interferon beta and glatiramer acetate have been mainstays of treatment in relapsingremitting multiple sclerosis for two decades. Remarkable advances in our understanding of immune function and dysfunction as well as increasingly sophisticated clinical trial design have stemmed from efforts to better understand these drugs. In this chapter, we review the history of their development and elaborate on known and theorized mechanisms of action. We describe the pivotal clinical trials that have led to their widespread use. We evaluate the clinical use of the drugs including tolerability, side effects, and efficacy measures. Finally, we look to the future of interferon beta and glatiramer acetate in the context of an ever growing armamentarium of treatments for relapsing remitting multiple sclerosis.


Interferon betaGlatiramer acetateMultiple sclerosis therapeuticsReviewHistory

Supplementary material

13311_2012_163_MOESM1_ESM.pdf (510 kb)
ESM 1(PDF 509 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2012

Authors and Affiliations

  1. 1.Department of Neurology, Albert Einstein College of Medicine, Division of Multiple SclerosisMontefiore Medical CenterBronxUSA
  2. 2.Corinne Goldsmith Dickinson Center for Multiple SclerosisMount Sinai School of MedicineNew YorkUSA